Table 5.
Best overall response to ASP3026 in the dose-expansion cohort
| Parameter | Expansion cohort ASP3026 525 mg (n = 16) |
|---|---|
| Best overall responsea, n (%) | |
| Complete response | 0 |
| Partial response | 8 (50) |
| Stable disease | 7 (44) |
| Progressive disease | 0 |
| Unable to evaluate | 1 (6) |
| Objective response (complete response + partial response) | |
| n (%) | 8 (50) |
| 95 % CIb | 25–75 % |
CI confidence interval
aBased on RECIST guidelines (v1.1) and International Working Group revised response criteria
bExact CI obtained using Clopper–Pearson method